COVID-19
9 competing products in clinical development for COVID-19.
Pipeline by Phase
Phase 27
Phase 32
All Products (9)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Bamlanivimab + Placebo + Etesevimab | Eli Lilly | Phase 3 | Completed | 77 |
| CT-P63 and CT-P66 / Placebo | Celltrion | Phase 3 | Withdrawn | 77 |
| Infliximab | Celltrion | Phase 2 | Completed | 52 |
| Human COVID-19 immunoglobulin (pH4) for intravenous injection + Placebo | Sinopharm | Phase 2 | UNKNOWN | 51 |
| Gimsilumab + Placebo | Roivant Sciences | Phase 2 | Completed | 49 |
| Mavrilimumab + Placebo | Kiniksa Pharmaceuticals | Phase 2 | Completed | 47 |
| Mavrilimumab + Placebos | Kiniksa Pharmaceuticals | Phase 2 | Completed | 47 |
| Mavrilimumab + Placebos | Kiniksa Pharmaceuticals | Phase 2 | Completed | 47 |
| Icosapent ethyl | Amarin Corporation | Phase 2 | Completed | 44 |